TIDMNSCI
RNS Number : 3347D
NetScientific PLC
27 October 2020
NetScientific plc
("NetScientific" or the "Company")
PDS Biotech Announces Initiation of Phase 2 Trial of PDS0101 in
Combination with Standard of Care Chemoradiotherapy in Advanced
Cervical Cancer
London, UK - 27 October 2020 - NetScientific plc (AIM: NSCI),
the life sciences and technology investment and commercialisation
company, announces that its portfolio company PDS Biotechnology
Corporation ("PDS") (Nasdaq: PDSB) today announced the Phase 2
clinical trial of PDS0101 in combination with standard of care
chemoradiotherapy (CRT) for treatment of locally advanced cervical
cancer is now open.
This Phase 2 trial is being led by Ann H. Klopp, M.D., Ph.D.,
Associate Professor of Radiation Oncology and Olsi Gjyshi, M.D.,
Ph.D., Resident in Radiation Oncology at The University of Texas MD
Anderson Cancer Center. The trial will investigate the anti-tumor
efficacy and safety of the PDS0101-CRT combination, and their
correlation with critical biomarkers of immune response, in
approximately 35 patients.
"We are excited to have initiated this Phase 2 human study of
PDS0101 administered with the current standard of care. We believe
that the demonstrated potential of PDS0101 to activate the immune
system to induce tumor-targeting T-cells provides strong potential
to present improved treatments to patients with cervical cancer,"
commented Dr. Lauren Wood, Chief Medical Officer of PDS
Biotech.
Dr. Ilian Iliev, Chief Executive Office of the Company and
Director of PDS Biotechnology said: "In line with NetScientific's
Strategic Review and stated plans, we supported PDS through two
successful public placements approximating $32m in 2020. The
resulting funding provided PDS with the resources and runway needed
to implement their ambitions development programme. We are pleased
at the continued progress of PDS in reaching the start of this
Phase 2 clinical trial with a prestigious partner."
NetScientific holds approximately 5.75% of PDS' undiluted share
capital.
The full details of the announcement are set out below and can
be found he re:
https://www.pdsbiotech.com/investors/news-center/press-releases/press-releases1/56-2020-news/443-iotechnnouncesnitiationofhase2rialof01020201026
# # #
PDS Biotech Announces Initiation of Phase 2 Trial of PDS0101 in
Combination with Standard of Care Chemoradiotherapy in Advanced
Cervical Cancer
PDS Biotech progresses second Phase 2 human clinical trial of
PDS0101
FLORHAM PARK, N.J., Oct. 26, 2020 (GLOBE NEWSWIRE) -- PDS
Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage
immunotherapy company developing novel cancer therapies and
infectious disease vaccines based on the Company's proprietary
Versamune(R) T-cell activating technology, today announced that the
Phase 2 clinical trial of PDS0101 in combination with standard of
care chemoradiotherapy (CRT) for treatment of locally advanced
cervical cancer is now open.
This Phase 2 trial is being led by Ann H. Klopp, M.D., Ph.D.,
Associate Professor of Radiation Oncology and Olsi Gjyshi, M.D.,
Ph.D., Resident in Radiation Oncology at The University of Texas MD
Anderson Cancer Center. The trial will investigate the anti-tumor
efficacy and safety of the PDS0101-CRT combination, and their
correlation with critical biomarkers of immune response, in
approximately 35 patients.
"We are excited to have initiated this Phase 2 human study of
PDS0101 administered with the current standard of care. We believe
that the demonstrated potential of PDS0101 to activate the immune
system to induce tumor-targeting T-cells provides strong potential
to present improved treatments to patients with cervical cancer,"
commented Dr. Lauren Wood, Chief Medical Officer of PDS
Biotech.
Dr. Lauren Wood, PDS Biotech's Chief Medical Officer, will serve
as PDS Biotech's liaison. The study is being performed pursuant to
an Investigator Initiated Study Agreement between PDS Biotech and
MD Anderson.
About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy company with a
growing pipeline of cancer immunotherapies and infectious disease
vaccines based on the Company's proprietary Versamune(R) T-cell
activating technology platform. Versamune(R) effectively delivers
disease-specific antigens for in vivo uptake and processing, while
also activating the critical type 1 interferon immunological
pathway, resulting in production of potent disease-specific killer
T-cells as well as neutralizing antibodies. PDS Biotech has
engineered multiple therapies, based on combinations of
Versamune(R) and disease-specific antigens, designed to train the
immune system to better recognize disease cells and effectively
attack and destroy them. To learn more, please visit
www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.
About PDS0101
PDS Biotech's lead clinical product, PDS0101, combines the
utility of the Versamune(R) platform with targeted antigens against
HPV-expressing cancers. In partnership with Merck & Co., PDS
Biotech is advancing a combination of PDS0101 and KEYTRUDA(R) to a
Phase 2 study in first line treatment of recurrent or metastatic
head and neck cancer. In partnership with the National Cancer
Institute (NCI), PDS Biotech is has initiated a phase 2 study
studying a combination of PDS0101 and two clinical-stage
immunotherapies to a Phase 2 study in advanced HPV-associated
cancers.
# # #
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulations (EU) No. 596/2014. Following the
publication of this announcement, this inside information is now
considered to be in the public domain.
For more information, please contact:
NetScientific
Ilian Iliev, CEO Tel: +44 (0)20 3514 1800
WH Ireland (NOMAD, Financial Adviser and Broker)
Chris Fielding / Darshan Patel Tel: +44 (0)20 7220 1666
About NetScientific
NetScientific is a life sciences and technology investment and
commercialisation Group, leveraging trans-Atlantic relationships
and global opportunities to deliver shareholder value.
For more information, please visit the website at www.NetScientific.net
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCGCBDGGXDDGGR
(END) Dow Jones Newswires
October 27, 2020 05:46 ET (09:46 GMT)
Netscientific (LSE:NSCI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Netscientific (LSE:NSCI)
Historical Stock Chart
From Apr 2023 to Apr 2024
